• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Trevi Therapeutics Inc.

    4/29/25 11:30:18 AM ET
    $TRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVI alert in real time by email
    DEFA14A
    false0001563880DEFA14A00015638802024-01-012024-12-31

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    TREVI THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     


     

    Your Vote Counts! TREVI THERAPEUTICS, INC. 2025 Annual Meeting Vote by June 10, 2025 11:59 PM ET TREVI THERAPEUTICS, INC. 195 CHURCH STREET, 16TH FLOOR NEW HAVEN, CT 06510 V72233-P29416 You invested in TREVI THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 11, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 28, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Vote in Advance of the Meeting Vote by June 10, 2025 11:59 PM ET Visit www.ProxyVote.com Vote Virtually at the Meeting* June 11, 2025 1:00 p.m. Eastern Time Smartphone users Point your camera here and vote without entering a control number Virtually at: www.virtualshareholdermeeting.com/TRVI2025 *Please check the meeting materials for any special requirements for meeting attendance.

    img25529448_0.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials, which contain important information and are available to you on the Internet at www.proxyvote.com. Please follow the instructions on the reverse side to vote these important matters. Board Voting Items Recommends 1.Election of two Class III directors to our Board of Directors, each to serve until the 2028 Annual Meeting of Stockholders. Nominees: 1a.Jennifer Good For1b.Anne VanLentFor2.Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.For3.Approval, on an advisory basis, of the compensation paid to our named executive officers.For4.Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers.1Year5.Approval of an amendment to the Trevi Therapeutics, Inc. 2019 Stock Incentive Plan to increase the number of shares available for issuance under the plan by 6,000,000 shares of common stock, and make certain other amendments. For NOTE: Transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement of the Annual Meeting. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V72234-P29416

     


     

    img25529448_1.jpg

     

     


    Get the next $TRVI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TRVI

    DatePrice TargetRatingAnalyst
    7/1/2025$25.00Overweight
    Cantor Fitzgerald
    5/28/2025$21.00Buy
    H.C. Wainwright
    3/10/2025$9.00 → $29.00Outperform → Strong Buy
    Raymond James
    3/10/2025$8.00 → $25.00Buy
    Needham
    12/12/2024$6.00 → $7.50Buy
    H.C. Wainwright
    9/9/2024$6.00 → $7.00Outperform
    Leerink Partners
    8/30/2024$6.00Buy
    H.C. Wainwright
    8/30/2024$9.00Outperform
    Raymond James
    More analyst ratings

    $TRVI
    SEC Filings

    See more
    • Trevi Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)

      6/17/25 5:00:32 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Trevi Therapeutics Inc.

      8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)

      6/4/25 4:18:35 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Trevi Therapeutics Inc.

      424B5 - Trevi Therapeutics, Inc. (0001563880) (Filer)

      6/4/25 4:14:38 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Trevi Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Trevi Therapeutics with a rating of Overweight and set a new price target of $25.00

      7/1/25 8:23:22 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Trevi Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $21.00

      5/28/25 9:09:46 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics upgraded by Raymond James with a new price target

      Raymond James upgraded Trevi Therapeutics from Outperform to Strong Buy and set a new price target of $29.00 from $9.00 previously

      3/10/25 8:08:41 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism

      NEW HAVEN, Conn., July 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will be attending Leerink Partners Therapeutics Forum: I&I and Metabolism, held from July 8-9 in Boston, Massachusetts. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeuti

      7/1/25 7:30:00 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

      NEW HAVEN, Conn., June 5, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 20,010,000 shares of its common stock at a public offering price of $5.75 per share, which includes 2,610,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the public offering at the

      6/5/25 4:30:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

      NEW HAVEN, Conn., June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 17,400,000 shares of its common stock at a public offering price of $5.75 per share, for total proceeds of $100 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering are being sold by Trevi. In ad

      6/3/25 10:15:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mathers Edward T

      4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

      6/13/25 4:09:28 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Meeker David P

      4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

      6/13/25 4:00:18 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Vanlent Anne

      4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)

      6/13/25 4:00:19 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Financials

    Live finance-specific insights

    See more
    • Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

      Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p<0.0001; 27 mg BID p<0.01); a -43.3% placebo-adjusted change from Baseline was achieved at the 108 mg BID dose group   Patients saw a rapid reduction in 24-hour cough frequency at Week 2, the first time point measured Haduvio was generally well-tolerated at all doses; discontinuation rates due to adverse events were similar in the Haduvio and placebo groups, 5.6% and 5.0%, respectively Trevi plans to request an End-of-Phase 2 meeting with the FDA later this year and is planning to initiate the Phase 3 program in the first half of 2026 Company to hos

      6/2/25 7:00:00 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

      Conference call and webcast to be held at 8:30 a.m. ET  NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced a conference call and live webcast taking place tomorrow, Monday, June 2nd, 2025, at 8:30 a.m. ET, to share topline results from the Phase 2b CORAL trial of Haduvio in patients with IPF chronic cough. www.trevitherapeuti

      6/1/25 4:00:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positive topline results from the Phase 2a RIVER trial in patients with refractory chronic cough Management to host a conference call and webcast today at 4:30 p.m. ET  NEW HAVEN, Conn., May 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC)

      5/8/25 4:05:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

      NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO).  www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte

      9/30/24 5:30:00 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

      Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical d

      4/2/24 7:30:00 AM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

      SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

      11/14/24 5:51:58 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Trevi Therapeutics Inc.

      SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

      11/13/24 4:30:24 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Trevi Therapeutics Inc.

      SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)

      11/8/24 6:57:55 PM ET
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care